Neumora Touts Brain Drug Wins Amidst Obesity Trial Setback

WATERTOWN, Mass. – March 30, 2026 – Neumora Therapeutics (Nasdaq: NMRA) today presented a picture of progress and pitfalls, announcing promising new data for its neuroscience pipeline while simultaneously revealing a significant delay for its obesity drug candidate. The clinical-stage biopharma company, which focuses on brain diseases, highlighted potentially class-leading results for its Alzheimer's agitation treatment and advanced a new candidate for schizophrenia, all while managing a preclinical toxicology issue that has pushed back its entry into the fiercely competitive weight-loss market.

The updates, part of its fourth quarter and full-year 2025 financial report, underscore the volatile nature of drug development. While the company ended the year with a solid $182.5 million in cash, projected to fund operations into the third quarter of 2027, its future hinges on converting clinical promise into proven therapies.

“We saw significant progress in 2025, laying the foundation for a catalyst-rich year ahead as we advance our pipeline of next-generation therapies for people living with brain diseases,” said Paul L. Berns, co-founder, chairman and chief executive officer of Neumora, in the company's press release.

A New Hope for Alzheimer's Agitation

The standout news from the announcement was new Phase 1b data for NMRA-511, a candidate for treating agitation in patients with Alzheimer’s disease. In a specific group of patients whose baseline agitation levels were comparable to those in pivotal trials for other drugs, NMRA-511 demonstrated what the company called an “unsurpassed clinical effect.”

The data showed a Cohen’s d effect size of 0.34 on a primary agitation scale and a more pronounced 0.51 on an aggression sub-score after eight weeks. While compelling, experts caution that comparing effect sizes across different trials can be misleading due to variations in study design and patient populations. Nonetheless, the results are encouraging in a field with high unmet need. Currently, Otsuka’s Rexulti (brexpiprazole) is the only drug specifically approved by the FDA for this challenging symptom of Alzheimer's.

Neumora also emphasized that NMRA-511 was well-tolerated, a critical factor for treatments aimed at a vulnerable, elderly population. The company plans to report data from a higher-dose study in the second half of 2026 and aims to initiate a larger Phase 2 study in the first quarter of 2027.

The Rocky Road of R&D: An Obesity Setback

In stark contrast to the positive neuroscience update, Neumora’s ambitions in the obesity space have hit a snag. The company’s candidate, NMRA-215, had previously shown strong potential in preclinical mouse studies, demonstrating weight loss comparable to the blockbuster drug semaglutide. The strategy was to position NMRA-215 as a maintenance therapy or as a new option for patients switching off existing treatments.

However, Neumora reported that a 13-week toxicology study in rats produced “unexpected adverse findings” in 5 of the 142 animals. The company stated its belief that the issue may be related to “study conduct” at the contract research organization (CRO) that ran the trial, noting the findings were not dose-dependent or linked to the drug's known mechanism.

As a result, Neumora is repeating the entire 13-week study with a different CRO. This has delayed the planned start of human clinical trials from the first half of 2026 to the first quarter of 2027. The setback not only pushes back timelines and increases costs but also means NMRA-215 will enter a market that is advancing at a breakneck pace, with giants like Novo Nordisk and Eli Lilly solidifying their dominance with powerful GLP-1 therapies.

A Diversified Pipeline and Anxious Investors

Beyond the mixed news, Neumora underscored the breadth of its pipeline. The company officially designated NMRA-898 as its lead program for schizophrenia. Based on promising Phase 1 data suggesting a potential for once-daily dosing, NMRA-898 is an M4 positive allosteric modulator (PAM), a novel mechanism for treating the complex disorder. Data from an ongoing study in healthy volunteers and patients is expected in the second half of 2026.

Meanwhile, all eyes are on the company’s navacaprant program for depression. After a previous study failed to meet its primary endpoint, Neumora is anticipating a joint data readout from two ongoing Phase 3 studies, KOASTAL-2 and -3, in the second quarter of 2026. With over 800 patients enrolled across both trials, this upcoming data is considered a major catalyst that could significantly impact the company’s valuation and strategic direction.

Financially, Neumora reported a net loss of $236.9 million for 2025, a slight decrease from the previous year, as it tightened its belt on R&D and administrative spending. The company's cash runway into late 2027 provides a buffer, but the clock is ticking. Wall Street analysts appear divided. Some, like those at Guggenheim, maintain a “Buy” rating, pointing to the pipeline's potential despite the obesity drug's delay. Others, like Stifel, hold a more cautious “Hold” rating, citing the high cash burn and development risks. The consensus view suggests that while Neumora has several promising shots on goal, the path forward is fraught with both significant opportunity and substantial risk.